Fresenius Kabi in talks to buy Akorn
The US generic drug manufacturer confirmed the talks in a US Securities and Exchange Commission (SEC) filing today.
Similarly, Fresenius said discussions are ongoing.
A spokesman for the German firm told us "Fresenius Kabi is currently in discussions with Akorn, Inc. concerning a potential acquisition."
He declined to comment further.